Readmission after lung resection is associated with increased costs and is used as a benchmark for quality. Outcomes of more than 22,000 lobectomies were evaluated for factors associated with readmission. 30- and 90-day readmission rates were 11.5% and 19.8%. Causes for readmission were pulmonary (24%), cardiovascular (16%), and surgical/procedura
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Surgery
January 30, 2016
January 23, 2016
Retrospective study of surgery versus SBRT for clinical stage I NSCLC using the National Cancer Data Base (NCDB). Propensity score matching was used to create 5355 matched pairs. In that analysis, median survival for those undergoing surgery was 62.3 months versus 33.1 months in those undergoing SBRT.
October 8, 2015
The authors evaluated a single year of thoracic surgery operations at their institution and compared outcomes based on data in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP), which uses a sampling technique, to the STS General Thoracic Database, a comprehensive data collection system. Globally, NSQIP under
September 20, 2015
A large retrospective study comparing 117618 patients from the National Cancer Database with Stage I NSCLC. 111731 received surgery, 5887 received SBRT. In a propensity managed comparison, those undergoing surgery had increased overall survival.
September 16, 2015
Outcomes of the California Cancer Registry for patients undergoing resection for Stage I NSCLC were evaluated according to Commission on Cancer (CoC) accreditation status and lung resection procedure volume. High volume hospitals (>50 annually) had better survival compared to medium (20-50 annually; HR 1.23) and low volume (<20 annually; 1.77)
September 12, 2015
This randomized trial compared induction therapy for pathologically-proven N2/IIIA NSCLC with 3 cycles of cisplatinum and docetaxel chemotherapy alone to chemotherapy combined with 44 Gy of radiation therapy. 232 pts in 23 centers were enrolled over a 12 year period. No differences were identified in the chemotherapy vs chemoradiotherapy groups for
August 20, 2015
Thus far, only 3 randomized controlled trials (RCTs) have compared stereotactive ablative radiotherapy (SABR) versus surgery in patients with early stage NSCLC (STARS trial, ROSEL trial, and ACOSOG Z4099 trial). Unfortunately all 3 were unable to meet the accrual goals and were closed early.
August 20, 2015
This is an invited commentary on the article by Chang and colleagues (Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials).
August 20, 2015
This expert opinion editorial is published in JTCVS in response to the article by Chang and colleagues. Meyers and colleagues begin by emphasizing that a large randomized controlled trial (RCT) would be the best way to answer the question of whether SABR or lobectomy is superior treatment for patients with early stage NSCLC.
August 20, 2015
This is a letter in response to the article by Chang and colleagues. The authors point out that only 58 patients were enrolled from 38 centers over 66.3 months, and speculate that this might be due to patients' preference for surgery.